Workflow
SHENYANG XINGQI PHARMACEUTICAL CO.(300573)
icon
Search documents
兴齐眼药(300573) - 2025年第一次临时股东大会决议公告
2025-06-13 09:16
证券代码:300573 证券简称:兴齐眼药 公告编号:2025-029 沈阳兴齐眼药股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 特别提示: 1、本次股东大会未出现否决议案的情形; 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、会议召开方式:本次会议以现场投票与网络投票相结合的方式召开。 2、现场会议时间:2025年6月13日(星期五)下午14:30。 3、网络投票时间:2025年6月13日,其中,通过深圳证券交易所交易系统进 行网络投票的具体时间为2025年6月13日9:15—9:25,9:30—11:30和13:00— 15:00;通过深圳证券交易所互联网投票系统进行网络投票的时间为2025年6月13 日9:15至15:00期间的任意时间。 4、现场会议召开地点:沈阳市浑南区泗水街68号,沈阳兴齐眼药股份有限 公司E1号楼,二楼多功能厅。 8、公司董事、监事、高级管理人员以及北京市竞天公诚律师事务所委派的 见证律师以现场的方式出席和列席了本次股东大会。 9、本次股东 ...
近视神药光环褪色,68岁创始人“割肉”融资8.5亿背后
Xin Lang Zheng Quan· 2025-06-05 01:34
Core Viewpoint - The company Xingqi Eye Medicine, which previously dominated the market with its unique "myopia miracle drug" atropine sulfate eye drops, is now facing unprecedented competition as major players like Heng Rui Medicine and Zhao Ke Ophthalmology have received approval for similar products, threatening its market position [1][2]. Group 1: Market Competition - The approval of 0.01% atropine sulfate eye drops in March 2024 significantly boosted Xingqi's revenue, with eye drop sales soaring by 106% to 1.366 billion yuan, contributing over 10% to total revenue [2]. - Competitors such as Heng Rui Medicine and Zhao Ke Ophthalmology are advancing with their own products, with Heng Rui's subsidiary having a substantial sales force of 8,910 compared to Xingqi's 1,197, indicating a potential market share threat [2]. Group 2: Financial Performance - Xingqi's financial performance has been volatile, with net profit soaring by 208% in 2019 due to internal sales rights, but growth slowed to 12.55% in 2022 following new regulations on online prescription drug sales [3]. - The company reported a resurgence in growth of 44.54% in 2024 after the approval of its product, but acknowledged risks of slowing growth and declining market share as the product becomes more widely available [3]. Group 3: Cash Flow and Funding Challenges - The company has invested over 600 million yuan in R&D from 2022 to 2024, representing more than 12% of its revenue, but cash reserves have plummeted from 515 million yuan to 370 million yuan, with short-term loans increasing by 185% to 200 million yuan [4]. - To address its financial challenges, the founder Liu Jidong has opted to dilute his stake through a fundraising effort of 850 million yuan, reducing his ownership from 28.63% to 22.02%, marking the second significant financing attempt in four years [4].
【盘中播报】138只个股突破半年线
Market Overview - As of 10:30 AM today, the Shanghai Composite Index stands at 3352.43 points, above the six-month moving average, with a change of 0.15% [1] - The total trading volume of A-shares today is 568.946 billion yuan [1] Stocks Performance - A total of 138 A-shares have surpassed the six-month moving average today, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Dahongli (300865) with a deviation rate of 17.40%, closing at 27.74 yuan, up 19.98% [1] - Huaxi Biological (688363) with a deviation rate of 6.97%, closing at 54.41 yuan, up 7.87% [1] - *ST Chengchang (001270) with a deviation rate of 5.20%, closing at 36.55 yuan, up 5.00% [1] Additional Stocks with Notable Performance - Other stocks with significant performance include: - Zhejiang Shuwenhua (600633) with a deviation rate of 5.17%, closing at 13.62 yuan, up 5.66% [1] - Gehua Cable (600037) with a deviation rate of 4.76%, closing at 7.73 yuan, up 6.47% [1] - Stocks with smaller deviation rates that have just crossed the six-month line include Aotai Biological, Chitianhua, and Emei Mountain A [1]
兴齐眼药(300573) - 关于SQ-22031滴眼液取得I期临床研究报告的提示性公告
2025-05-29 10:36
沈阳兴齐眼药股份有限公司(以下简称"公司")研发的 SQ-22031 滴眼液近 日获得了"评估 SQ-22031 滴眼液在健康受试者中单次/多次给药的安全性、耐受 性和药代动力学的单中心、随机、双盲、安慰剂对照的 I 期临床试验"临床研究 报告。根据《深圳证券交易所上市公司自律监管指引第 4 号——创业板行业信息 披露》的有关规定,现将主要内容公告如下: 一、基本情况 证券代码:300573 证券简称:兴齐眼药 公告编号:2025-028 沈阳兴齐眼药股份有限公司 关于 SQ-22031 滴眼液取得 I 期临床研究报告的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整,没有 虚假记载、误导性陈述或重大遗漏。 本次公告的 SQ-22031 滴眼液适应症为神经营养性角膜炎。截至本公告披露 日,经查询国家药品监督管理局网站,尚无同品种药品批准上市。 1 药品名称:SQ-22031 滴眼液 剂型:滴眼剂 注册分类:治疗用生物制品 1 类 适应症:神经营养性角膜炎 临床试验批准通知书编号:2024LP01687、2024LP01688、2024LP01689、 2024LP01690 临床试验分期: ...
兴齐眼药营收净利连增6年 拟募不超8.5亿建研发中心
Chang Jiang Shang Bao· 2025-05-28 23:50
Core Viewpoint - Xingqi Eye Pharmaceutical is actively enhancing its technological capabilities and research and development (R&D) capacity through a planned stock issuance to raise up to 850 million yuan for R&D center construction and working capital supplementation [1][2][4]. Fundraising and Investment - The company plans to issue shares to specific investors, raising no more than 850 million yuan, with the net proceeds allocated entirely to the R&D center project and working capital [2][3]. - The stock issuance will not exceed 30% of the total share capital prior to the issuance, amounting to a maximum of 73.6 million shares [2]. - The R&D center aims to create a benchmark in the ophthalmology field, integrating smart laboratory matrices and collaborative innovation platforms, with a total investment of 984 million yuan [3]. Financial Performance - Xingqi Eye Pharmaceutical has achieved continuous growth in revenue and net profit for six consecutive years from 2019 to 2024 [1][6]. - In Q1 2025, the company reported a revenue of 536 million yuan, a year-on-year increase of 53.24%, and a net profit of 146 million yuan, soaring by 319.86% [6][7]. - The gross margin for Q1 2025 reached 80.16%, an increase of 4.06 percentage points year-on-year, while the net margin was 27.21%, up by 17.28 percentage points [7]. R&D Focus and Team - The company emphasizes R&D as the core driver of its development, holding 72 invention patents and 60 approved ophthalmic drug numbers, with 38 products included in the medical insurance directory [4][5]. - As of December 31, 2024, the company had 271 R&D personnel, accounting for 11.17% of the total workforce, with a significant portion holding master's degrees or higher [5]. Market Position and Strategy - Xingqi Eye Pharmaceutical is recognized as a leading domestic company in ophthalmic drug R&D, with a diverse product line covering various categories of eye medications [6]. - The company aims to enhance its competitive edge through differentiated innovation and to establish itself as an innovation-driven pharmaceutical enterprise [4].
兴齐眼药再度定增募资遭投资者“用脚投票”,公司货币资金连年下降
Bei Jing Shang Bao· 2025-05-28 12:48
消息面上,兴齐眼药发布的2025年度向特定对象发行股票预案显示,公司拟募集资金不超过(含)8.5亿元,扣除发行费用后的募集资金净额全部投资于研发中 心建设项目及补充流动资金,拟分别投入募资额6.5亿元、2亿元。 兴齐眼药表示,通过本次募投项目的实施,公司将打造国际视野的综合型研发总部,全面提升公司的研发实力,拓宽公司产品管线,优化公司现有产品结 构,突破技术壁垒,通过差异化创新形成竞争优势,为公司带来新的利润增长点。 这是兴齐眼药时隔四年再度进行定增募资。在2020年9月,兴齐眼药曾发布2020年度向特定对象发行A股股票预案,在最初的预案中,公司拟定增募资不超8 亿元。 值得一提的是,兴齐眼药此次定增募资的募投项目,与2020年的募投项目出现重合,均包含研发中心建设项目。 具体来看,此次预案显示,研发中心建设项目总投资金额9.84亿元,其中前次募集资金投入金额为2.08亿元,本次募集资金拟投入6.5亿元。目前本项目已启 动建设,计划于2027年底前建设完成。 抛出定增募资计划后,5月28日,兴齐眼药(300573)遭到了投资者"用脚投票"。 交易行情显示,5月28日,兴齐眼药低开2.5%,开盘后,公司股价不断 ...
兴齐眼药拟定增募资不超过8.5亿元 进一步加码研发提升创新能力
Zheng Quan Ri Bao Wang· 2025-05-28 11:49
专注于眼科药物领域的沈阳兴齐眼药(300573)股份有限公司(以下简称"兴齐眼药")拟通过定增融资进 一步加码研发创新,提升企业的发展动能。据兴齐眼药5月27日晚间披露的定增预案,公司拟通过向特 定对象发行股票的方式募集资金不超过8.5亿元,其中6.5亿元用于研发中心建设项目,2亿元用于补充流 动资金。 "研发中心项目有助于加强技术研发和创新能力,提高公司的核心竞争力。补充流动资金有助于应对市 场变化和竞争压力,增强公司的抗风险能力。"澳大利亚资深注册会计师谢宗博向《证券日报》记者表 示,如果募投项目最终都能顺利实施,将有助于推动兴齐眼药的业务增长和可持续发展。 经营业绩持续高增长 据公告,兴齐眼药此次募投的研发中心建设项目旨在构建眼科领域标杆案例,打造集智能实验室矩阵、 跨国研发协作中枢、产学研协同创新平台为一体的研发中心,搭建精准制剂技术、多维药理评价、整合 式药代评价、药物包材研究等平台。该项目将搭建智慧化管理系统,可加速药物研发成果转化与上市进 程,构建集智能化、精准化、高效化于一体的国际一流眼科研发基地。 全面提升研发实力 兴齐眼药是一家主要从事眼科药物研发、生产、销售的高新技术企业。公司于2016 ...
兴齐眼药: 关于2025年度向特定对象发行股票摊薄即期回报的风险提示及填补回报措施和相关主体承诺的公告
Zheng Quan Zhi Xing· 2025-05-27 11:24
证券代码:300573 证券简称:兴齐眼药 公告编号:2025-024 沈阳兴齐眼药股份有限公司 关于 2025 年度向特定对象发行股票摊薄即期回报的风险提 示及填补回报措施和相关主体承诺的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 重大事项提示: 以下关于沈阳兴齐眼药股份有限公司(以下简称"公司"、 "本公司"、 "发行 人")本次向特定对象发行股票后其主要财务指标的分析、描述均不构成公司的 盈利预测,投资者不应仅依据该等分析、描述进行投资决策,如投资者据此进行 投资决策而造成任何损失的,公司不承担任何责任。本公司提示投资者,制定填 补回报措施不等于对公司未来利润做出保证。 公司第五届董事会第九次会议和第五届监事会第九次会议审议通过了《关于 公司 2025 年度向特定对象发行股票预案的议案》等与本次向特定对象发行股票 ("本次发行")相关的议案。本次发行募集资金总额不超过(含)85,000.00 万元,同时本次发行股票数量不超过本次发行前公司总股本的 30%,即不超过 下简称"深交所")审核通过和中国证券监督管理委员会(以下简称"中国证监 会")作 ...
兴齐眼药: 沈阳兴齐眼药股份有限公向特定对象发行股票募集资金使用可行性分析报告
Zheng Quan Zhi Xing· 2025-05-27 11:24
证券代码:300573 证券简称:兴齐眼药 沈阳兴齐眼药股份有限公司 SHENYANG XINGQI PHARMACEUTICAL CO., LTD. (中国(辽宁)自由贸易试验区沈阳片区新运河路 25 号) 募集资金使用可行性分析报告 二〇二五年五月 沈阳兴齐眼药股份有限公司 2025 年度向特定对象发行股票募集资金使用可行性分析报告 一、募集资金使用计划 本次拟募集资金总额不超过(含)85,000.00 万元,募集资金扣除发行费用后 的净额全部用于下列项目建设,具体情况如下: 单位:万元 序号 项目名称 总投资额 拟使用募集资金 占比 合计 118,423.20 85,000.00 100.00% 项目投资总额超出募集资金净额部分由公司以自有资金或通过其他融资方 式解决。公司董事会可根据股东大会的授权,对项目的募集资金投入顺序和金额 进行适当调整。若公司在本次发行募集资金到位之前根据公司经营状况和发展规 划,对项目以自筹资金先行投入,则先行投入部分将在本次发行募集资金到位之 后以募集资金予以置换。 若实际募集资金数额少于上述项目拟投入募集资金投资金额,在最终确定的 本次募投项目范围内,公司将根据实际募集资 ...
兴齐眼药: 前次募集资金使用情况鉴证报告
Zheng Quan Zhi Xing· 2025-05-27 11:24
Core Viewpoint - The report provides a detailed account of the fundraising activities and the utilization of the raised funds by Shenyang Xingqi Eye Pharmaceutical Co., Ltd. as of December 31, 2024, highlighting the financial figures and project statuses [1][2][3]. Fundraising Overview - The company raised a total of RMB 599,669,492.10 through the issuance of 5,763,282 shares, with actual funds received amounting to RMB 581,870,425.73 after deducting underwriting fees [1][2]. - The funds were fully received by December 22, 2021, and verified by a certified public accountant [1]. Fund Utilization - As of December 31, 2024, the total amount of funds utilized was RMB 382,520,531.09, with remaining funds of RMB 195,077,792.24 held in a dedicated bank account [2][3]. - The company has not changed the investment projects but adjusted the implementation locations for certain projects, specifically the "R&D Center Construction" project [2][3]. Project Status and Economic Benefits - The "Single-Dose Production Line Construction" project is expected to achieve an internal rate of return of 51.96% and a net present value of RMB 904,582,400, with an anticipated annual revenue of RMB 1,970,283,200 once operational [4]. - The "R&D Center Construction and New Drug Development" project aims to enhance the company's R&D capabilities, although direct economic benefits cannot be quantified at this stage due to the nature of drug development processes [4]. Financial Summary - The total amount of funds raised was RMB 599,669,492.10, with cumulative usage amounting to RMB 399,868,000, indicating a significant portion of the funds has been allocated to various projects [3][4]. - The company has approved the permanent allocation of surplus funds to supplement working capital, reflecting a strategic financial management approach [2][3].